Compare Adaptive Biotechnologies Corp (ADPT) vs KLA Corp. (KLAC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs KLA Corp. — how do they compare? Adaptive Biotechnologies Corp trades at $19.96 (market cap $3.33B), while KLA Corp. trades at $220.5 (market cap $282.77B). The key difference: KLA Corp. is far larger — about 84.9× Adaptive Biotechnologies Corp's market cap, and KLA Corp. pays a 0.43% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | KLAC | |
|---|---|---|
Market Cap | $3.33B | $282.77B |
Sector | Health | Technology |
52-Week High | $22.37 | $301.71 |
52-Week Low | $10.24 | $84.39 |
Enterprise Value | $3.19B | $283.96B |
Dividend Yield | — | 0.43% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
KLA Corporation (KLAC) trades at $216.47, down 8.1% over 24 hours, amid a broader semiconductor selloff. The stock maintains strong fundamentals with a 35.66% net income margin and consistent earnings beats, including Q1 2026 EPS of $0.94 versus $0.917 expected. A 1:10 stock split is scheduled for June 12, 2026, and the company pays a $2.30 dividend. Technical indicators show a bearish short-term trend with support near $209.
KLAC's outlook is supported by robust profitability and AI-driven demand, but high valuation ratios (P/E 66.07) pose risks. Analyst consensus is bullish with a $228.42 price target, though sector volatility and competitive pressures require monitoring. The stock offers growth potential tempered by market sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About KLA Corp.
KLA designs and manufactures yield-management and process-monitoring diagnostic and control systems for the semiconductor manufacturing industry. The systems are used to analyze the manufacturing process at various steps in a semiconductor's development. The firm's laser-scanning products are used for wafer qualification, process monitoring, and equipment monitoring. KLA also provides inspection tools and systems for optical metrology and e-beam metrology.
Read more on KLAC →
